- Olema Pharmaceuticals intends to raise $170 million in a U.S. IPO of its common stock.
- The firm is developing treatments for women’s cancers, most particularly various breast cancers.
- It has a collaboration with major pharma firm Novartis and I value its focus on breast cancer treatments, so the IPO is worth considering.
- Looking for more investing ideas like this one? Get them exclusively at IPO Edge. Get started today »
Quick Take
Olema Pharmaceuticals (OLMA) intends to raise $170 million from the sale of its common stock in an IPO, according to an amended registration statement.
The company is a clinical stage biopharma seeking treatments for women’s cancers.
OLMA has a strong focus on breast cancer, positive initial results and collaboration agreement with a major pharma.
For life science investors with an 18 to 24-month hold time frame, the IPO is worth consideration.
Company & Technology
San Francisco, California-based Olema was founded to develop treatments for various forms of breast cancer.
Management is headed by president and CEO Sean Bohen, M.D., Ph.D., who has been with the firm since 2020 and was previously EVP Global Medicines at AstraZeneca (AZN).
Below is a brief overview video of ER+ breast cancer:
